Antibody Discovery & Development Strategies
11th October 2012 — 12th October 2012

Implementing New Antibody Methodologies to Strengthen the Target Selection Process and Improve Function and Efficiency

Key Conference Speakers:

Lihui Xu
Principal Scientist, Merrimack Pharmaceuticals

David Meininger, Ph.D., M.B.A.
Senior Director, Biologics Discovery, Merck & Co., Inc.

Mitchell Ho, Ph.D.
Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH

Andrew E. Nixon, Ph.D
Vice President, Lead Discovery & Biochemistry, Discovery Research , Dyax Corp.

Conference Overview:
Delegates will attend this program to learn about the latest advancements in antibody discovery and development, including cutting-edge research on how to identify the correct target for an antibody, and how to streamline the entire development process to get more products out and reduce budget needs.

Attendees will also hear about hot topics such as bispecifics and the latest advancements in antibody drug conjugates (ADCs) and their impact on certain critical therapeutic areas. Key to the conference will be addressing a need for quality antibodies and learning about what leading companies such as Genentech, Bayer, Intrexon and Merck are producing in the way of new antibody treatments.

Follow us on Social Media:

Twitter: www.twitter.com/pharmame
Event Hashtag: #antibody2012
LinkedIn: http://www.linkedin.com/groups/Life-Sciences-Pharma-marcus-evans-3116273/about?trk=anet_ug_grppro

Suggested Attendees

Vice Presidents, Directors, Chief Scientific Officers, Senior Scientists from the pharmaceutical and biotechnology industries: Antibody discovery, Antibody development, Monoclonal antibodies, Protein development

Expected Number of Attendees

50-100

View Conference Website: Antibody Discovery & Development Strategies

Price of Attendance

Email ddrey@marcusevansch.com for details.

Brochure

View Event Brochure

Location

San Francisco
San Francisco
San Francisco
United States
San Francisc